NCT06190951 2026-02-10
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
Regeneron Pharmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
University of Southern California
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals